According to TipRanks.com, Souda has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -9.6% and a 37.8% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Bio-Techne with a $502.00 average price target.
Bio-Techne’s market cap is currently $14.54B and has a P/E ratio of 67.60.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is neutral on the stock. Last month, Charles Kummeth, the CEO of TECH sold 5,104 shares for a total of $1,862,960.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community. The Protein Platforms segment develops, manufactures, and sells tools to simplify protein analysis. The Diagnostics segment includes blood chemistry and blood gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market worldwide. The company was founded on 1976 and is headquartered in Minneapolis, MN.
Read More on TECH:
- Thermo Fisher (TMO) Gets a Buy Rating from SVB Securities
- Ord Minnett Thinks Macquarie Group Limited’s Stock is Going to Recover
- Stephens Reaffirms Their Buy Rating on Nicolet Bankshares (NIC)
- Investors Cheer for Texas Instruments’ Upbeat Q2 Results
- Nicolet Bankshares (NIC) Gets a Buy Rating from Ladenburg Thalmann & Co.